WANY
FOLD

Wealthspire Advisors (New York)’s Amicus Therapeutics FOLD Stock Holding History

Wealthspire Advisors (New York)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$788 – 1698
2025
Q3 		$788 Buy
+100
New +$712 ﹤0.01% 2774

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wealthspire Advisors (New York)'s FOLD Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 100 shares — an estimated $788 sold.

Wealthspire Advisors (New York) first reported a position in FOLD in Q3 2025 and held it in 1 quarter. The position peaked at $788 in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 100 Amicus Therapeutics shares in Q4 2025, an estimated $788.
  • Wealthspire Advisors (New York) first reported a position in Amicus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Amicus Therapeutics position peaked at $788 in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.